Lessons to Learn for Adequate Targeted Therapy Development in Metastatic Colorectal Cancer Patients

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Insulin-like growth factor 1 receptor (IGF1R) is a receptor tyrosine kinase crucial for cell growth and proliferation.
• IGF1R pathway dysregulation is common in cancers, including colorectal cancer, similar to EGFR, HER2, and MET.
• Key signaling cascades involve PI3K-AKT and MAPK-MEK pathways.

Purpose of the Study:

• To review and discuss novel therapeutic strategies for drug development targeting IGF1R.
• To address intrinsic and acquired resistance mechanisms in metastatic colorectal cancer (mCRC).
• To explore the role of post-translational modifications, EMT, and tumor microenvironment in IGF1R pathway resistance.

Main Methods:

• Literature review and synthesis of current research on IGF1R signaling.
• Analysis of resistance mechanisms including SUMOylation, EMT, and microenvironment interactions.
• Discussion of emerging drug development approaches for mCRC.

Main Results:

• IGF1R pathway activation is a significant driver in colorectal cancer progression.
• Resistance to IGF1R-targeted therapies can arise from various biological processes.
• Understanding these resistance mechanisms is critical for effective treatment design.

Conclusions:

• Targeting the IGF1R pathway presents a promising avenue for treating metastatic colorectal cancer.
• Developing strategies to overcome resistance mechanisms is essential for therapeutic success.
• Further research into novel drug development is warranted for patients with mCRC.